JAC Advance Access originally published online on August 5, 2006
Journal of Antimicrobial Chemotherapy 2006 58(4):848-852; doi:10.1093/jac/dkl315
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mutators among CTX-M ß-lactamase-producing Escherichia coli and risk for the emergence of fosfomycin resistance
1 Antibiotic Resistance Monitoring and Reference Laboratory, Centre for Infections, Health Protection Agency 61 Colindale Avenue, London NW9 5EQ, UK 2 Laboratory of Health Care Associated Infection, Centre for Infections, Health Protection Agency London, UK 3 Barts and The London School of Medicine and Dentistry London, UK
Received 10 May 2006; returned 30 May 2006; revised 7 July 2006; accepted 12 July 2006
*Corresponding author. Tel +44-208-8327-7236; Fax +44-208-8327-6264; E-mail: matthew.ellington{at}hpa.org.uk
Objectives: Fosfomycin is a possible oral treatment for lower urinary tract infections caused by Escherichia coli with CTX-M extended-spectrum ß-lactamases but is vulnerable to mutational resistance. Hypermutability among natural E. coli populations might facilitate the emergence of resistance to fosfomycin. We therefore examined the prevalence of mutators amongst urinary isolates of E. coli producing CTX-M ß-lactamases.
Methods: Urinary E. coli isolates with CTX-M ß-lactamases (n = 220) were screened for resistance to both rifampicin and fosfomycin, as well as a mutator phenotype, by rifampicin and fosfomycin disc assays. Mutation frequencies for 10 isolates, identified as mutators by the initial disc screen, were determined in triplicate on agar with rifampicin or fosfomycin at 4x MIC and with fosfomycin or nitrofurantoin at 256 mg/L.
Results: The disc screen identified 10 likely mutators and quantitative tests indicated that 9 of these had mutation frequencies of 8.0 x 10–6–1.5 x 10–4 for fosfomycin and 0.1–2.3 x 10–6 for rifampicin. These mutators were diverse in terms of PFGE type and 4 of the 10 were confirmed as strong mutators with rifampicin and fosfomycin. Only the strongest mutator isolate and hypermutable MutS– control strain consistently gave single-step mutants resistant to 256 mg/L fosfomycin. No nitrofurantoin-resistant mutants were selected from any isolate, although they could be selected from the hypermutable MutS– control strain.
Conclusions: Mutator phenotypes were found among E. coli expressing CTX-M ß-lactamases and were independent of strain type. These had an increased propensity to fosfomycin resistance.
Keywords: hypermutators , nitrofurantoin , UTIs
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. J. Knottnerus, S. Nys, G. ter Riet, G. Donker, S. E. Geerlings, and E. Stobberingh Fosfomycin tromethamine as second agent for the treatment of acute, uncomplicated urinary tract infections in adult female patients in The Netherlands? J. Antimicrob. Chemother., August 1, 2008; 62(2): 356 - 359. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. N. Stepanova, M. Pimkin, A. A. Nikulin, V. K. Kozyreva, E. D. Agapova, and M. V. Edelstein Convergent In Vivo and In Vitro Selection of Ceftazidime Resistance Mutations at Position 167 of CTX-M-3 {beta}-Lactamase in Hypermutable Escherichia coli Strains Antimicrob. Agents Chemother., April 1, 2008; 52(4): 1297 - 1301. [Abstract] [Full Text] [PDF]
|
|